TP53 Deletion is Not an Adverse Feature in Multiple Myeloma Treated with Total Therapy 3

Documenti analoghi

• International Staging System and Metaphase Cytogenetic Abnormalities in the Era of Gene Expression Profiling Data in Multiple Myeloma Treated with Total Therapy 2 and 3 Protocols
  di: Waheed, Sarah, et al.
  Pubblicazione: (2010)
• Cytogenetic Abnormalities in Multiple Myeloma: Poor Prognosis Linked to Concomitant Detection in Random and Focal Lesion Bone Marrow Samples and Associated with High-Risk Gene Expression Profile
  di: Zhou, Yiming, et al.
  Pubblicazione: (2009)
• Superior results of Total Therapy 3 (2003-33) in gene expression profiling–defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance
  di: Nair, Bijay, et al.
  Pubblicazione: (2010)
• Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols
  di: Hoering, Antje, et al.
  Pubblicazione: (2009)
• Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy
  di: van Rhee, Frits, et al.
  Pubblicazione: (2010)